Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Issue 6 (27th December 2014)

• Record Type: Journal Article
• Authors: Hutterer, Markus; Hattingen, Elke; Palm, Christoph; Proescholdt, Martin Andreas; Hau, Peter
• Is Part Of: Neuro-oncology. Volume 17:Issue 6(2015:Jun.)
• Page Start: 784
• Page End: 800
• Publication Date: 2014-12-27
• Subjects: high-grade glioma -- antiangiogenic treatment -- MRI -- PET -- multimodal response assessment; Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/nou322
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Despite multimodal treatment, the prognosis of high-grade gliomas is grim. As tumor growth is critically dependent on new blood vessel formation, antiangiogenic treatment approaches offer an innovative treatment strategy. Bevacizumab, a humanized monoclonal antibody, has been in the spotlight of antiangiogenic approaches for several years. Currently, MRI including contrast-enhanced T1-weighted and T2/fluid-attenuated inversion recovery (FLAIR) images is routinely used to evaluate antiangiogenic treatment response (Response Assessment in Neuro-Oncology criteria). However, by restoring the blood–brain barrier, bevacizumab may reduce T1 contrast enhancement and T2/FLAIR hyperintensity, thereby obscuring the imaging-based detection of progression. The aim of this review is to highlight the recent role of imaging biomarkers from MR and PET imaging on measurement of disease progression and treatment effectiveness in antiangiogenic therapies. Based on the reviewed studies, multimodal imaging combining standard MRI with new physiological MRI techniques and metabolic PET imaging, in particular amino acid tracers, may have the ability to detect antiangiogenic drug susceptibility or resistance prior to morphological changes. As advances occur in the development of therapies that target specific biochemical or molecular pathways and alter tumor physiology in potentially predictable ways, the validation of physiological and metabolic imaging biomarkers will become increasingly important in the near future.